Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 5/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29590104 | 1.00 | KCNQ3 (0.49) | KCNQ3KCNQ2MAPTTP53LMNA | |
| SCHEMBL14783207 | 0.94 | KCNQ3 (0.47) | KCNQ3KCNQ2MAPTTP53LMNA | |
| SCHEMBL29590017 | 0.94 | KCNQ3 (0.47) | KCNQ3KCNQ2MAPTTP53LMNA | |
| SCHEMBL29590313 | 0.94 | MAPT (0.48) | KCNQ3KCNQ2MAPTTP53LMNA | |
| SCHEMBL14783015 | 0.94 | MAPT (0.48) | KCNQ3KCNQ2MAPTTP53LMNA | |
| SCHEMBL14783517 | 0.93 | KCNQ3 (0.42) | KCNQ3KCNQ2MAPTTP53LMNA | |
| SCHEMBL29591614 | 0.93 | KCNQ3 (0.42) | KCNQ3KCNQ2MAPTTP53LMNA | |
| SCHEMBL14783011 | 0.92 | MTOR (0.52) | KCNQ3KCNQ2MTOREPHX2 | |
| SCHEMBL14783380 | 0.92 | HDAC3 (0.49) | KCNQ3KCNQ2MAPTTP53LMNA | |
| SCHEMBL29591549 | 0.92 | MTOR (0.52) | KCNQ3KCNQ2MTOREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10065932-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2018-09-04 | — | — | US | claimed |
| US-20180134669-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2018-05-17 | — | — | US | claimed |
| EP-2755657-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2017-11-29 | — | — | EP | claimed |
| US-9518029-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2016-12-13 | — | — | US | claimed |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-11 | — | — | US | claimed |
| EP-2755657-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-23 | — | — | EP | claimed |
| WO-2013040515-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-21 | — | — | WO | claimed |
| CN-115403531-A | Chemical entities, compositions, and methods as kinase inhibitors | 润新生物公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20220251049-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2022-08-11 | — | — | US | disclosed |
| CN-108794411-B | Certain chemical entities, compositions, and methods | 润新生物公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10759766-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3332785-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2755657-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9822081-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170183316-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-06-29 | — | — | US | disclosed |
| US-9518029-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-11 | — | — | US | disclosed |
| EP-2755657-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013040515-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183316-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | KCNQ3 1219/4885KCNQ2 604/4885MAPT 3567/4885 |
| US-10065932-B2 | Certain chemical entities, compositions, and methods | BRAF, NRAS, KRAS | KCNQ3 1219/4885KCNQ2 604/4885MAPT 3567/4885 |
| US-20180134669-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | KCNQ3 1219/4885KCNQ2 604/4885MAPT 3567/4885 |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | KCNQ3 1219/4885KCNQ2 604/4885MAPT 3567/4885 |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | KCNQ3 1107/4885KCNQ2 529/4885MAPT 3397/4885 |
| US-10759766-B2 | Certain chemical entities, compositions, and methods | BRAF, NRAS, KRAS | KCNQ3 1107/4885KCNQ2 529/4885MAPT 3397/4885 |
| US-20220251049-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | KCNQ3 1107/4885KCNQ2 529/4885MAPT 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.